Skip to main content

Medulloblastoma, Childhood

3
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Y-mAbs Therapeutics
Y-mAbs TherapeuticsNY - New York
1 program
1
177Lu-DTPA-omburtamabPhase 1/2Monoclonal Antibody2 trials
Active Trials
NCT07698899Recruiting18Est. Jul 2030
NCT04167618Terminated2Est. Aug 2022
Senhwa Biosciences
Senhwa BiosciencesCA - San Diego
1 program
1
CX 4945Phase 1/21 trial
Active Trials
NCT03904862Terminated21Est. Aug 2025
Prevail Therapeutics
1 program
1
LY2940680Phase 11 trial
Active Trials
NCT01697514Withdrawn0Est. Jul 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Y-mAbs Therapeutics177Lu-DTPA-omburtamab
Senhwa BiosciencesCX 4945
Y-mAbs Therapeutics177Lu-DTPA-omburtamab
Prevail TherapeuticsLY2940680

Clinical Trials (4)

Total enrollment: 41 patients across 4 trials

NCT04167618Y-mAbs Therapeutics177Lu-DTPA-omburtamab

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

Start: Sep 2021Est. completion: Aug 20222 patients
Phase 1/2Terminated
NCT03904862Senhwa BiosciencesCX 4945

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Start: Jul 2019Est. completion: Aug 202521 patients
Phase 1/2Terminated
NCT07698899Y-mAbs Therapeutics177Lu-DTPA-omburtamab

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

Start: Jul 2026Est. completion: Jul 203018 patients
Phase 1Recruiting
NCT01697514Prevail TherapeuticsLY2940680

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Start: Jul 2013Est. completion: Jul 20160
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 41 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.